2care4 Generics specializes in the development, registration and marketing of generic RX medicinal products for the Nordic markets. We are rapidly expanding our portfolio across a wide range of therapeutic areas via pharmacies and hospital tenders in Denmark, Sweden, Norway and Finland.
2care4 registered its first generic product, Etodolac (a non-steroidal anti-inflammatory drug) in 2013. Since then several marketing authorization have been obtained in the Nordic markets across a wide range of therapeutic areas. To ensure a solid foundation for future expansion of the generic portfolio, 2care4 Generics was in 2015 established as an independent subsidiary. Today 2care4 has 10+ generic marketing authorisations and more than 20 generic products in the pipeline.
The 2care4 Group has a proven track record of +10 years of profitable presence in the Nordics. With the aid of our self-developed business intelligence and marketing surveillance system, we can immediately evaluate the potential of any given product including competitor overview, price trends, market development and provide corresponding forecasts. We exhibit an excellent understanding of the price mechanisms in the countries where we are actively present and due to a profound knowledge of our competitors and market mechanisms, we are fully capable in engaging ourselves in long-term profitable commitments.
Are you our new partner?
We are looking for new partners within co-development, in-licensing and representation in the Nordics. Taking our business very seriously, 2care4 Generics will do its outmost to be an excellent partner with respect to innovation, quality and power to act.
Please contact us via email@example.com to learn more about 2care4 Generics and the possibilities for a mutual beneficial business. With an entrepreneurial approach and agile organization, potential partners will be assured a fast, detailed and reliable feedback on any query.